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Dendritic cells as Achilles’ heel and
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virus infection
Günther Schönrich* and Martin J. Raftery
Institute of Medical Virology, Helmut-Ruska-Haus, Charité-Universitätsmedizin Berlin, Berlin, Germany
Varicella zoster virus (VZV), a human alphaherpesvirus, causes varicella and subsequently
establishes latency within sensory nerve ganglia. Later in life VZV can reactivate to cause
herpes zoster. A reduced frequency of VZV-specific T cells is strongly associated with
herpes zoster illustrating that these immune cells are central to control latency. Dendritic
cells (DCs) are required for the generation of VZV-specific T cells. However, DCs can
also be infected in vitro and in vivo allowing VZV to evade the antiviral immune response.
Thus, DCs represent the immune systems’ Achilles heel. Uniquely among the human
herpesviruses, VZV infects both DCs and T cells, and exploits both as Trojan horses.
During primary infection VZV-infected DCs traffic to the draining lymph nodes and tonsils,
where the virus is transferred to T cells. VZV-infected T cells subsequently spread infection
throughout the body to give the typical varicella skin rash. The delicate interplay between
VZV and DCs and its consequences for viral immune evasion and viral dissemination will
be discussed in this article.
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Introduction
In 1943 Helmut Ruska discovered that the virus particles isolated from varicella lesions and those
isolated from zoster lesions had identical morphology (Ruska, 1943). The virus was subsequently
named varicella zoster virus (VZV). Together with herpes simplex virus (HSV) type 1 and 2
it represents the human alphaherpesviruses (Arvin and Gilden, 2013). After transmission VZV
replicates in epithelial cells of the upper respiratory tract. Subsequently, cell-associated viremia is
observed which is followed by the appearance of skin infection, giving the typical varicella rash
(commonly known as chickenpox) after an incubation period of 10–21 days.
After primary infection has been resolved VZV establishes latency in the dorsal ganglia of nerve
cells that innervate the affected skin. It can reactivate, mostly in immunosuppressed individuals
and in elderly adults, resulting in herpes zoster (commonly known as shingles) after anterograde
transport to the corresponding dermatome. Skin blisters that occur during varicella and zoster
harbor high numbers of infectious particles. The main route of transmission is through cell free
virus particles that are carried by aerosols of infectious respiratory tract secretions or vesicular fluid.
Pathological consequences of VZV include congenital varicella syndrome (Sauerbrei and Wutzler,
2000) and postherpetic neuralgia (PHN; Gnann and Whitley, 2002).
More than 30 years ago a live attenuated vaccine (vOka) was developed from the Oka parental
strain (pOka; Takahashi et al., 1974). Intriguingly, vOka is a mixture of pOka genomes with distinct
patterns of mutations (Gomi et al., 2002). In 1995 vOka was introduced in the United States and is
now licensed for routine use in many countries worldwide. This resulted in significant reduction
of the VZV-associated disease burden. Although complications are rare in childhood infection,
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adult infection, common in tropical countries, induces a more
severe clinical course (Lee, 1998). The incidence and severity of
herpes zoster increases with age. It was first postulated in 1965
that this is due to a decline in VZV-specific immunity (Hope-
Simpson, 1965). It is now accepted that boosting VZV-reactive T
cells in older adults using vOka is effective in preventing herpes
zoster (Oxman et al., 2005; Gagliardi et al., 2012). Dendritic cells
(DCs) are professional antigen-presenting cells that are key to a
successful antiviral immune response. Upon sensing a pathogen
DCs not only mount an innate response but also specifically
instruct the adaptive immune system. This results in the activation
of effector mechanisms that are tailor-made for the infecting
pathogen (Medzhitov, 2007; Volz et al., 2012; Maisonneuve et al.,
2014). Thus, DCs bridge the innate and adaptive arms of the
immune system and orchestrate the different immune cells. In
this review, we will discuss how VZV exploits DCs for its own
purposes.
Tropism of VZV for DC Subsets
In the absence of inflammation (steady state) two main groups of
DCs are observed in the skin and mucosa of the respiratory tract:
conventional DCs (cDCs) and Langerhans cells (LCs; Pulendran,
2015). They migrate continuously via the lymphatics to draining
lymph nodes. This migration is considerably increased during
inflammation. cDCs subsets are derived from committed pro-
genitor DCs in the bone marrow that traffic through the blood
to peripheral tissue where they undergo a final differentiation
step. In contrast, LCs are maintained independently of circulating
progenitor DCs originating in the bone marrow. Migratory DCs
form an intricate network that functions as a sentinel system in the
peripheral tissue. Upon encounter with pathogens such as VZV
they take up antigen and migrate through the lymphatics to the
draining lymph nodes. They can localize in the T cell zone to
present pathogen-derived antigen and activate specific T lympho-
cytes. Plasmacytoid DCs (pDCs), which produce large amounts of
type I interferon (IFN) in response to viruses, fully differentiate in
the bone marrow before they populate the lymphoid organs and
become resident DCs.
Under inflammatory conditions during infection human
monocytes can also develop in vivo into so-called inflamma-
tory DCs (mo-DCs; Segura et al., 2013). Equivalent DCs can
be generated in vitro by culturing CD14+ human monocytes in
the presence of granulocyte-macrophage colony-stimulating fac-
tor (GM-CSF) and interleukin (IL)-4 and subsequently exposing
them to maturation stimuli such as CD40L or tumor necrosis
factor (TNF)-a (Sallusto and Lanzavecchia, 1994). Thesemo-DCs
represent themost frequently used in vitroDCmodel and are per-
missive to VZV (Abendroth et al., 2001b; Morrow et al., 2003; Hu
and Cohen, 2005; Gutzeit et al., 2010). VZV-infected immature
mo-DCs do not undergo DNA fragmentation (Abendroth et al.,
2001b) but can acquire other characteristics of cell death such as
impaired membrane integrity and phosphatidylserine exposure
(Gutzeit et al., 2010). The open reading frame (ORF) 47 encodes
a serine/threonine protein kinase and promotes VZV replication
in immature mo-DCs thereby enhancing spread of VZV to other
cells (Hu and Cohen, 2005).
In the skin VZV affects both the dermis, wheremigratory cDCs
reside, and the epidermis, where LCs are located (Nikkels et al.,
1993). Both LCs and dermal cDCs isolated ex vivo are susceptible
to VZV infection (Gutzeit et al., 2010). In VZV-infected human
skin lesions the frequency and distribution of DC subsets changes
most likely due to immigration and emigration similar to HSV-
infected mouse skin (Eidsmo et al., 2009). The frequency of LCs
is drastically reduced implying activation and migration of LCs
to draining lymph nodes (Gutzeit et al., 2010; Huch et al., 2010).
In contrast, an influx of other DCs such as inflammatory mo-
DCs (Gutzeit et al., 2010) and pDCs (Gerlini et al., 2006; Huch
et al., 2010) is observed. Skin biopsies from varicella lesions show
occasional cDCs, pDCs, and LCs that express VZV proteins sug-
gestive of VZV infection. Most likely, LC egress is induced by
cytokines released during VZV infection. In accordance, inflam-
matory cytokines such as TNF-a or IL-1b are known to trigger LC
migration (Cumberbatch et al., 1997). It is possible that migratory
LCs represent the main route for transport of virus and viral
antigen to the lymph nodes.
Role of DCs in VZV Dissemination
Varicella zoster virus-infected patients are extremely contagious.
Primary VZV infection is by droplets of infectious saliva or
respiratory tract secretions (Suzuki et al., 2004). Intriguingly,
intraepithelial DCs in the lung extend cellular processes into
the air lumen allowing continuous surveillance of the luminal
surface of the alveoli and airways (Jahnsen et al., 2006) similar
to gut DCs (Rescigno et al., 2001). Accordingly, these DCs are
probably amongst the first cells to interact with VZV. The DC
tropism and resultant migration permits VZV to shuttle to the
tonsils and the regional lymph nodes. There, VZV-infected DCs
establish intimate contact and infect T lymphocytes, as has been
demonstrated in vitro (Abendroth et al., 2001b).
Confirming a role for T cells in shuttling virus to the skin VZV
lesions appeared in human skin grafts of severe combined immun-
odeficiencymice (SCID) after injection of VZV-infected humanT
cells (Ku et al., 2004). Further evidence for the concept of a DC/T
cells-axis during VZV dissemination comes from experiments
with the closely related simian varicella virus (SVV; Messaoudi
et al., 2009). Infected DC-like cells were detected in the lung of
African greenmonkeys after intratracheal infectionwith recombi-
nant enhanced green fluorescent protein (EGFP)-expressing SVV
and transport the virus to the draining lymph nodes where it
infects memory T cells (Ouwendijk et al., 2013). Other immune
cells in the blood including DCs were also infected with SSV
and may contribute to the hematogenous transfer of virus to the
skin. The possible DC/T cells-axis during VZV dissemination is
illustrated in Figure 1.
There are still open questions concerning this concept. Firstly,
it has not been tested whether VZV-infected DCs still respond
to chemotactic signals and are able to migrate in vivo, although
the absence of LC in VZV skin lesions and the ability to infect
primary LCs ex vivo strongly suggest this (Gutzeit et al., 2010;
Huch et al., 2010). Secondly, virus cell-to-cell transmission ismore
than the sum of virus release and entry as these processes have
to be coordinated and channeled to the site of cell-to-cell contact
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FIGURE 1 | Model of DC-assisted viral dissemination during primary
VZV infection. After inhalation of VZV-containing aerosols intraepithelial DCs
that extend projections into the lumen of the airways, analogous to
“snorkeling,” pick up VZV directly or from infected epithelial cells. Upon
recognition of VZV through PRRs such as TLR2 intraepithelial DCs and
possibly other cells infected with VZV start to migrate to the lung-draining
lymph nodes in the first phase of cell-associated viral dissemination. At this
site, DCs transfer VZV to memory T cells which subsequently carry VZV in the
second phase of cell-associated viral dissemination to the skin. VZV-infected
memory T cells infect keratinocytes either directly or indirectly through
infection of other skin-resident cells which subsequently transfer the virus to
keratinocytes. Finally, VZV replicating in the skin causes the typical rash
followed by latent infection of sensory neurons.
(Mothes et al., 2010). Thus far, the molecular details of how DCs
transfer VZV to T cells have not been defined. It is possible but
not proven that this process is similar to the DC-to-T cell trans
infection observed duringHIVpathogenesis (Rinaldo, 2013). This
trans infection requires an intimate DC/T cell contact through
membrane molecules and the formation of a virological synapse
across which the virions are transferred. In addition, it is unclear
whichDC subset(s), epidermal and/or dermalDCs, transfersVZV
to T cells in vivo. Finally, it has not been investigated whether
mature DCs are more effective in transferring VZV to T cells as
it is the case with HIV (Izquierdo-Useros et al., 2007).
VZV-associated Innate Signaling
Although DC and T cells can serve as Trojan horses, they also
represent an enormous risk to the virus: DCs efficiently initiate
the antiviral defense. Innate immune responses are triggered by
virus-associated components through pattern recognition recep-
tors (PRRs) such as toll-like receptors (TLRs; Vandevenne et al.,
2010). Intact VZV virions activate innate signaling in monocytes
and macrophages via TLR2 located on the cell membrane (Wang
et al., 2005). However, the corresponding viral ligand has not
yet been defined. Possibly, VZV-encoded glycoproteins in the
viral envelope are involved similar to HSV (Leoni et al., 2012). A
recent publication has shown that theVZV-encoded deoxyuridine
triphosphate nucleotidohydrolase (dUTPase), a non-structural
viral protein, induces TLR2-dependent secretion of inflammatory
cytokines in DCs generated fromCD34+ human stem cells (Ariza
et al., 2014). Similar to other herpesviruses, the VZV-encoded
dUTPasemay be released by infected cells after induction of apop-
tosis or pyroptosis before it binds to TLR2 on the cell membrane.
Alternatively, VZV-encoded dUTPase could be released through
exosomes as demonstrated for Epstein-Barr virus, a gammaher-
pesvirus (Ariza et al., 2013).
Herpesviruses have developed diverse and numerous strategies
to interfere with innate immune responses (Vandevenne et al.,
2010). VZV prevents translocation of NF-kB subunits into the
nucleus of mo-DCs (Sloan et al., 2012). This inhibition requires
the E3 ubiquitin ligase domain of VZVORF61 and is downstream
of triggering receptors such as TLR3, TLR8, and TLR9. It is
possible that further VZV proteins target NF-kB signaling. More-
over, it has been demonstrated that VZVORF61 down-modulates
the interferon regulatory factor (IRF) 3-mediated IFN-b pathway
(Zhu et al., 2011). In accordance, infection of rhesus macaques
with recombinant SVV lacking ORF61 resulted in an increased
frequency of pDCs and increased expression of IFN-b as well as
IL-6, which is dependent onNF-kB activation (Meyer et al., 2013).
SVV ORF61 encodes a 54.1-kDa polypeptide that is homologous
to VZV ORF61 and to other alpha herpesvirus proteins that are
encoded in similar regions of the viral genome such as HSV-
encoded infected cell protein 0 (ICP0). HSV ICP0 also inhibits
the induction of IFN-stimulated genes with the help of its E3
ubiquitin ligase domain (Eidson et al., 2002; Lin et al., 2004).
Moreover, several other VZV proteins interfere with type I IFN-
mediated responses by targeting IRF3 activation includingORF62
(Sen et al., 2010) andORF47 (Vandevenne et al., 2011). These viral
proteins are most likely also functional in VZV-infected pDCs as
they no longer produce type I IFN (Huch et al., 2010). InVZV skin
accumulations of pDCs were observed (Gerlini et al., 2006; Huch
et al., 2010). Similarly, after intrabronchial infection of rhesus
macaques with SVV increased frequencies of pDCs are found
that correlate with enhanced type I IFN production and a rapid
decrease in viral load (Haberthur et al., 2014). These results impli-
cate that pDCs are recruited to the site of VZV replication to sup-
port the antiviral host defense, however type I IFN release is inhib-
ited in VZV-infected pDCs by not yet defined mechanisms. Upon
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stimulation pDCs are also able to present viral antigen and prime
virus-specific T cells (Colonna et al., 2004). It is likely but not yet
proven that VZV also interferes with T cell stimulation by pDCs.
Modulation of Adaptive Immune
Responses by VZV
T cells not only transport VZV to the skin but also play a pivotal
role in controlling VZV during primary infection (Malavige et al.,
2008). Decreased VZV specific immunity in elder individuals is
associated with increased risk for herpes zoster. This strongly sug-
gests that T cells also control VZV reactivation (Hope-Simpson,
1965; Burke et al., 1982; Levin et al., 2003). At the time being it is
unclear whether and howDCs contribute to control of latent VZV
by memory T cells.
Varicella zoster virus interferes with T cell responses similar
to most other herpesviruses (Smith and Khanna, 2013). For this
purpose it targets DCs, which promote Th1-like adaptive immune
responses by providing three major signals to T cells (Figure 2A).
Signal 1 is delivered by antigen presentation through major
histocompatibility complex (MHC) molecules whereas signal 2,
also called costimulatory signal, is mediated by CD40, CD80,
and CD86. Proinflammatory cytokines released by DCs, mainly
IL-12 and type I IFN, represent a third signal that drives Th1-like
adaptive immune responses. VZV clearly weakens signal 1–3 by
targeting DCs (Figure 2B). After infection of mature mo-DCs
VZV impairs signal 1 by downregulation of MHC class I (Aben-
droth et al., 2001a) as well as signal 2 by reducing surface density
of CD80 and CD86 (Morrow et al., 2003). As a consequence of
these phenotypic changes VZV-infected mo-DCs have a reduced
capacity to stimulate allogeneic T lymphocytes. On the molecular
level it has been found that VZV ORF66, a protein kinase, retains
mature MCH class I complexes in the cis/medial Golgi (Aben-
droth et al., 2001a; Eisfeld et al., 2007). By which mechanism(s)
VZV downregulates costimulatory molecules on mature mo-DCs
is unknown. In addition, VZV-infected DCs also express dimin-
ished levels of CD83, an important maker of mature DCs, similar
to mature DCs infected with HSV, or human cytomegalovirus
(Kruse et al., 2000; Morrow et al., 2003; Senechal et al., 2004).
Central to viral immune evasion is the third signal which can
be blocked only by VZV clinical strains but not by vOka, the
VZV vaccine strain (Gutzeit et al., 2010). Efficient IL-12 secre-
tion and Th1-polarization by DCs requires priming of DCs by
synergistic signaling through multiple PRRs (Schulz et al., 2000;
Napolitani et al., 2005; Roses et al., 2008) and is facilitated by
innate T cells (Leslie et al., 2002; Fujii et al., 2007). In fact, TLRs
control key functions of DCs and mediate signals that play a
pivotal role in initiation of adaptive immune responses (Iwasaki
and Medzhitov, 2004). In accordance, the VZV-associated block
of IL-12 secretion was due to impaired signaling downstream
of TLR2 (Gutzeit et al., 2010). TLR2 is triggered by VZV, most
likely by a viral glycoprotein within the viral envelope and dUT-
Pase released from VZV-infected cells (Wang et al., 2005; Ariza
et al., 2013). Peripheral blood mononuclear cells from humans
vaccinated with vOka produce high amounts of IL-12 after res-
timulation in vitro (Jenkins et al., 1998). This is in line with the
notion that vOka instructs DCs to promote an efficient Th1-type
FIGURE 2 | Evasion of DC function by VZV. (A) Stimulated uninfected DCs
can induce efficient antiviral Th1-like adaptive immune responses by providing
three signals to antiviral T cells. Virus-derived antigen (Ag) is presented by
MHC molecules (signal 1) and recognized by the T cell-receptor (TCR) on T
cells. Costimulatory molecules such as CD80 and CD86 interact with CD28
expressed by T cells (signal 2). DCs integrate stimuli received through a
combination of different PRRs and release type I IFN and IL-12.
(B) VZV-infected DCs are no longer able to deliver signal 1–3 to antiviral T
cells. MHC as well as costimulatory molecules are downregulated. Moreover,
VZV clinical strains but not the vaccine strain interfere with PRR-induced
innate signaling resulting in the inability to release type I IFN and IL-12.
Together, these functional changes prevent VZV-infected DCs to mount an
effective antiviral Th1-like adaptive immune response.
of adaptive immune response. This instructive capability makes
vOka a prime candidate vector for the development of novel vac-
cines. Its genome is large enough to accommodate even largeDNA
inserts encoding antigenic structures from other viral pathogens
using bacterial artificial chromosome technology (Somboonthum
et al., 2007; Matsuura et al., 2013).
Concluding Remarks
In this article we have discussed how VZV, one of the most
successful human pathogens, exploits DCs to disseminate in the
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human organism, evade the antiviral immune responses and
cause disease. In contrast, vOka, the only live attenuated vaccine
available against human herpesviruses, does not cause significant
disease. Although both wild type VZV and vOka target DCs
only DCs infected with vOka can be instructed to become a
Th1-promoting antigen-presenting cell. It will be important in
the future to precisely define on the molecular level how DCs
infected with wild type VZV differ from those infected with vOka.
Moreover, it is necessary to pinpoint the viral proteins responsible.
A better understanding of these differences could allow to design
desperately needed vaccines against other human herpesviruses.
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